Description:Idasanutlin is a small molecule inhibitor that primarily targets the MDM2 protein, which is known for its role in regulating the p53 tumor suppressor pathway. By inhibiting MDM2, Idasanutlin promotes the stabilization and activation of p53, leading to increased apoptosis in cancer cells that rely on MDM2 for survival. This compound is particularly relevant in the treatment of various malignancies, including those with wild-type p53, as it can restore the function of this critical tumor suppressor. Idasanutlin is typically administered orally and has been evaluated in clinical trials for its efficacy and safety in treating hematological malignancies and solid tumors. Its mechanism of action highlights the importance of the p53 pathway in cancer biology, making it a significant candidate in targeted cancer therapies. Additionally, Idasanutlin's pharmacokinetics, including absorption, distribution, metabolism, and excretion, are crucial for understanding its therapeutic potential and optimizing treatment regimens.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
